Lantern Pharma presents clinical data from LP-284

Lantern Pharma (LTRN) announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress, held October 14-17 in New York City. The presentation featured a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma who experienced rapid disease progression following four prior treatment regimens, including CAR-T cell therapy and bispecific antibody therapy. The patient achieved complete metabolic response with non-avid lesions after just two 28-day cycles of LP-284, administered intravenously on days 1, 8, and 15 of each cycle. At study entry, the patient presented with extensive multifocal bony lesions following treatment failure with R-CHOP chemotherapy, radiation therapy, a CD19 CAR-T, and a CD3xCD20 bispecific antibody. This clinical outcome validates LP-284’s synthetic lethal mechanism and addresses the critical gap for patients who have exhausted advanced targeted and immunotherapies. AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284’s mechanism of action. A novel differentiated synthetic lethal mechanism targeting DNA repair deficiencies via transcription-coupled nucleotide excision repair, enabling activity regardless of TP53 mutation status or surface antigen expression while overcoming BTK inhibitor and proteasome inhibitor resistance and demonstrating preclinical combination synergy with approved antibody therapies. LP-284 addresses the post-CAR-T, post-bispecific treatment gap in both monotherapy and combination settings, targeting a $3-4 billion annual market in relapsed/refractory B-cell cancers. The LL&M Congress poster titled, A Phase 1 Study of LP-284 in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphomas and Solid Tumors, generated interest from both biopharma companies and clinical investigators.